Scarica l'app Stockscreener
111.42
1.28%
-1.44
Dopo l'orario di chiusura:
113.59
2.17
+1.95%
Precedente Chiudi:
$112.86
Aprire:
$109.23
Volume 24 ore:
313.71K
Relative Volume:
0.99
Capitalizzazione di mercato:
$1.64B
Reddito:
$1.30M
Utile/perdita netta:
$-130.19M
Rapporto P/E:
-13.28
EPS:
-8.3898
Flusso di cassa netto:
$-131.94M
1 W Prestazione:
-8.87%
1M Prestazione:
+19.66%
6M Prestazione:
+55.55%
1 anno Prestazione:
+302.97%
Intervallo 1D:
$107.22
$113.95
Intervallo di 1 settimana:
$94.00
$128.54
Portata 52W:
$26.19
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
111.42 | 1.66B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - Stock Titan
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com South Africa
Director-linked trust plans $57.9K INBX stock sale - Stock Titan
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data - TipRanks
Inhibrx (INBX) director buys 2,500 shares via family trust - Stock Titan
Inhibrx Biosciences (INBX) chief boosts stake with 25,000-share buy - Stock Titan
80% response in HPV+ head and neck cancer lifts Inhibrx (INBX) trial plans - Stock Titan
Why Inhibrx Biosciences (INBX) Stock Is Down Today - Quiver Quantitative
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates - TradingView
Inhibrx reports INBRX-106 Phase 2 cancer trial results - grafa.com
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial - Seeking Alpha
Inhibrx Biosciences Announces Primary Endpoint Results from Phase 2 HexAgon Study Of INBRX-106 In Combination With Pembrolizumab In HNSCC - marketscreener.com
Phase 2 primary endpoint results for INBRX106 revealed by Inhibrx Biosciences in HNSCC trial - Traders Union
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study - PR Newswire
(INBX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study - AOL.ca
Cancer drug study results are due Sept. 8 from Inhibrx - Stock Titan
INBX Q2 2026 Earnings: Loss of $2.34 per Share Beats Consensus, Stock FlatEarnings Quality Analysis - vinanet.vn
Inhibrx Biosciences (INBX) Holds at $124.97 as Range-Bound Trading ContinuesRVOL Breakout - vinanet.vn
Inhibrx Biosciences advances Ewing sarcoma research with ozekibart trial - Traders Union
Inhibrx Biosciences (INBX) Slips to $124.66 as Biotech Momentum CoolsDemand Zone - vinanet.vn
Inhibrx stock trades above $120 as latest deal reshapes the biotech story - ad-hoc-news.de
INBX stock steadies near $120 as losses widen in latest quarter - ad-hoc-news.de
Citizens reiterates Market Perform on Inhibrx Biosciences stock By Investing.com - Investing.com Canada
Inhibrx (INBX) Momentum: Records a 4.52% Increase to $103.63 in the Latest Reading; Next Test: the Session Ends Within the Reported Technical Boundaries on the DayIV Percentile - vinanet.vn
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com - Investing.com Canada
Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus - Sahm
Inhibrx (INBX) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Available Record; Trading Response: The Market Price Declines 2.92% in the Available RecordNegative Surprise Momentum - vinanet.vn
Western Standard LLC Takes $4.45 Million Position in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx (INBX) Q1 2026 Results: EPS Falls Short of Its Estimate in the Current Update; Market Move: The Stock Gains 7.25% at the CloseEarnings Stability Report - vinanet.vn
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Elevated Pipeline InvestmentReturn On Capital - vinanet.vn
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors? - simplywall.st
Trading the Move, Not the Narrative: (INBX) Edition - Stock Traders Daily
Inhibrx Biosciences expands clinical evaluation of Ozekibart in new cancer study cohorts - Traders Union
Inhibrx Biosciences (INBX) Falls 8.9% to $88.37 as Downside Pressure BuildsUp Down Ratio - vinanet.vn
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Inhibrx (INBX): Viking Global group discloses 9.3% beneficial ownership stake - Stock Titan
Inhibrx Biosciences (INBX) Slides 8% to $89.22: Support at $84.76 Becomes Key TestNHNL Divergence - vinanet.vn
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained - TipRanks
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):